Literature DB >> 43224

Biotransformation of furosemide in patients with acute pulmonary edema.

J Perez, D S Sitar, R I Ogilvie.   

Abstract

Furosemide (20-80 mg) was administered iv over 5 min to 16 patients with the diagnosis of acute pulmonary edema due to left heart failure. Serum and urine samples collected during the 24 hr after administration were assayed for furosemide and its biotransformation products by gas-liquid chromatography. A biexponential decay of serum furosemide concentrations vs. time was observed. Recovery of furosemide and its metabolites from urine in 24 hr varied between 30 and 98% of the administered dose. The excretion of unchanged drug accounted for 22.6-73.4% of the dose. The excretion of the glucuronide metabolite and 2-amino-4-chloro-5-sulfamoylanthranilic acid accounted for 3.3-40.4% and from 0.13-3.92% of the dose, respectively. Urinary excretion of furosemide was less in patients with, than in those without, myocardial infarction. Urinary excretion of the oxidative acidic metabolite was increased in patients with reduced creatinine clearance. The glucuronide metabolite of furosemide was the major biotransformation product in these patients with acute pulmonary edema.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 43224

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  The pharmacokinetics of frusemide are influenced by age.

Authors:  F Andreasen; U Hansen; S E Husted; J A Jansen
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

Review 3.  Reactive metabolites in the biotransformation of molecules containing a furan ring.

Authors:  Lisa A Peterson
Journal:  Chem Res Toxicol       Date:  2012-10-24       Impact factor: 3.739

Review 4.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Kinetic disposition and diuretic effect of frusemide in acute pulmonary oedema.

Authors:  J Perez; D S Sitar; R I Ogilvie
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

6.  Disposition and pharmacodynamics of diuretics and antihypertensive agents in renal disease.

Authors:  B L Mirkin; T P Green; R F O'Dea
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

Review 7.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.